Cancer Screening Rates Returning to Pre-Pandemic Levels
By February 2023, the end of the third year after the start of the COVID-19 pandemic, in-person cancer screening rates are returning to pre-pandemic levels for breast, colorectal, and cervical cancers. Individuals with chronic conditions had higher screening rates and were more likely to have returned to pre-pandemic screening levels.
Previous studies have documented drops in cancer screening during the COVID-19 pandemic. Cancer screenings are an essential component of cancer prevention and treatment. Screening tests can identify pre-cancerous tissue or cancer while it is at an early stage before other symptoms are present.
This analysis examined trends in common cancer screening tests that are performed in person—for breast, cervical, and colorectal cancers —to determine whether rates had returned to pre-pandemic levels by the end of February 2023, three years after the start of the COVID-19 public health emergency. Cancer screening trends were analyzed separately by health status defined by number of chronic conditions.
Related Public Policy Research
Characteristics of the Patient-Provider Relationship and Impact on Colorectal Cancer Screening
Colorectal cancer is the second leading cause of death from cancer, even though it is highly preventable. This report examines the impact that shared racial identity between patient and provider has on the likelihood of colorectal cancer screening.
Understanding the Medicare Advantage Program
Medicare Advantage (MA) plans provide enrollees a valuable alternative to Medicare fee-for-service (FFS) by offering out-of-pocket cost protections, additional benefits, and innovative strategies for care management and coordination.
The opioid epidemic is projected to claim 1.2 million U.S. lives this decade without new efforts to stem the crisis. Policymakers can leverage COVID-19 pandemic era learnings, such as the use of telehealth, the continuation of cross-state licensure, and the employment of peers, to implement measures that support sustained access to evidence-based solutions for the delivery of care to individuals with OUD.
Subscribe
Keep up with our latest news, research, and stories.
Subscribe to financial alerts on our investors site